GlassScriptPhysician profile
William G Broderick
NPI 1689648248
$2,347.76
in general payments reported to CMS, 2019-2025
26 companies · $297 in 2025
The $297 reported for 2025 was more than what 84% of Pediatrics providers received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $168 · 2021: $254 · 2022: $285 · 2023: $426 · 2024: $790 · 2025: $297.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,512.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,512.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ironshore Pharmaceuticals INC. | $355.97 | 2019-2024 | Jornay Pm |
| Supernus Pharmaceuticals, INC. | $267.63 | 2024-2025 | Qelbree |
| Corium, LLC | $258.08 | 2022-2025 | Azstarys |
| Pfizer INC. | $197.61 | 2021-2025 | |
| Sanofi-Aventis U.S. LLC | $168.54 | 2024-2025 | |
| Merck Sharp & Dohme LLC | $154.36 | 2019-2025 | Gardasil 9, Vaxneuvance, M-M-R II |
| Takeda Pharmaceuticals U.S.A., INC. | $149.66 | 2019-2021 | |
| Glaxosmithkline, LLC. | $119.10 | 2019-2025 | Bexsero |
| Tris Pharma INC | $108.75 | 2019-2022 | |
| Cranial Technologies, INC | $103.72 | 2020-2024 | Doc Band |
| Neos Therapeutics, LP | $73.72 | 2023-2024 | Cotempla Xr-Odt |
| Kaleo, INC. | $45.53 | 2019-2022 | |
| Acadia Pharmaceuticals INC | $45.36 | 2025 | Daybue |
| Astrazeneca Pharmaceuticals LP | $43.64 | 2024 | Flumist Quadrivalent |
| Sanofi Pasteur INC. | $40.91 | 2021-2023 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $27.90 | 2025 | Jornay Pm |
| Alk-Abello, INC | $24.35 | 2025 | Neffy |
| Biomarin Pharmaceutical INC. | $24.09 | 2022 | |
| Neurelis, INC. | $20.97 | 2023 | Valtoco |
| Mayne Pharma Commercial LLC | $19.87 | 2024 | |
| Ars Pharmaceuticals Operations, INC. | $18.04 | 2025 | Neffy |
| Seqirus USA INC | $18.03 | 2022 | |
| Ironwood Pharmaceuticals, INC | $16.99 | 2024 | |
| Rhodes Pharmaceuticals L.P. | $16.71 | 2019 | |
| Genentech USA, INC. | $14.50 | 2019 | |
| Adlon Therapeutics L.P. | $13.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw William Broderick listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.